Literature DB >> 31876392

Hearing loss in individuals with osteogenesis imperfecta in North America: Results from a multicenter study.

Keren Machol1,2, Trevor D Hadley1, Jake Schmidt1, David Cuthbertson3, Henri Traboulsi4,2, Rodrigo C Silva4,2, Chloe Citron5, Sobiah Khan5, Kate Citron5, Erin Carter5, Kenneth Brookler5, Jay R Shapiro6,7, Robert D Steiner8,9, Peter H Byers10,11, Francis H Glorieux12, Michaela Durigova12, Peter Smith13, Michael B Bober14, Vernon R Sutton1,2, Brendan H Lee1,2, Sandesh C S Nagamani1,2, Cathleen Raggio5.   

Abstract

Hearing loss (HL) is an extra-skeletal manifestation of the connective tissue disorder osteogenesis imperfecta (OI). Systematic evaluation of the prevalence and characteristics of HL in COL1A1/COL1A2-related OI will contribute to a better clinical management of individuals with OI. We collected and analyzed pure-tone audiometry data from 312 individuals with OI who were enrolled in the Linked Clinical Research Centers and the Brittle Bone Disorders Consortium. The prevalence, type, and severity of HL in COL1A1/COL1A2-related OI are reported. We show that the prevalence of HL in OI is 28% and increased with age in Type I OI but not in Types III and IV. Individuals with OI Types III and IV are at a higher risk to develop HL in the first decade of life when compared to OI Type I. We also show that the prevalence of SNHL is higher in females with OI compared to males. This study reveals new insights regarding prevalence of HL in OI including a lower general prevalence of HL in COL1A1/COL1A2-related OI than previously reported (28.3 vs. 65%) and high prevalence of SNHL in females. Our data support the need in early routine hearing evaluation in all types of OI that can be adjusted to the severity of the skeletal disease.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Type I collagen; hearing loss; natural history study; osteogenesis imperfecta

Mesh:

Substances:

Year:  2019        PMID: 31876392      PMCID: PMC7385724          DOI: 10.1002/ajmg.a.61464

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  42 in total

1.  Gillette Functional Assessment Questionnaire 22-item skill set: factor and Rasch analyses.

Authors:  George E Gorton; Jean L Stout; Anita M Bagley; Katherine Bevans; Tom F Novacheck; Carole A Tucker
Journal:  Dev Med Child Neurol       Date:  2010-11-18       Impact factor: 5.449

2.  Impact of alendronate on quality of life in children with osteogenesis imperfecta.

Authors:  Mouin G Seikaly; Sashi Kopanati; Nina Salhab; Pamela Waber; Diane Patterson; Richard Browne; John A Herring
Journal:  J Pediatr Orthop       Date:  2005 Nov-Dec       Impact factor: 2.324

Review 3.  Osteogenesis imperfecta.

Authors:  P H Byers; R D Steiner
Journal:  Annu Rev Med       Date:  1992       Impact factor: 13.739

4.  Multidisciplinary Treatment of Severe Osteogenesis Imperfecta: Functional Outcomes at Skeletal Maturity.

Authors:  Kathleen Montpetit; Telma Palomo; Francis H Glorieux; François Fassier; Frank Rauch
Journal:  Arch Phys Med Rehabil       Date:  2015-07-02       Impact factor: 3.966

Review 5.  Modern approach to children with osteogenesis imperfecta.

Authors:  Leonid Zeitlin; François Fassier; Francis H Glorieux
Journal:  J Pediatr Orthop B       Date:  2003-03       Impact factor: 1.041

6.  Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

Authors:  L M Ward; F Rauch; M P Whyte; J D'Astous; P E Gates; D Grogan; E L Lester; R E McCall; T A Pressly; J O Sanders; P A Smith; R D Steiner; E Sullivan; G Tyerman; D L Smith-Wright; N Verbruggen; N Heyden; A Lombardi; F H Glorieux
Journal:  J Clin Endocrinol Metab       Date:  2010-11-24       Impact factor: 5.958

7.  Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I.

Authors:  Frank Rauch; Liljana Lalic; Peter Roughley; Francis H Glorieux
Journal:  Eur J Hum Genet       Date:  2010-01-20       Impact factor: 4.246

8.  Normal gross motor development: the influences of race, sex and socio-economic status.

Authors:  A J Capute; B K Shapiro; F B Palmer; A Ross; R C Wachtel
Journal:  Dev Med Child Neurol       Date:  1985-10       Impact factor: 5.449

9.  A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.

Authors:  Nick Bishop; Rachel Harrison; Faisal Ahmed; Nick Shaw; Richard Eastell; Mike Campbell; Elizabeth Knowles; Claire Hill; Christine Hall; Steve Chapman; Alan Sprigg; Alan Rigby
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

10.  Physical activity in youth with osteogenesis imperfecta type I.

Authors:  A Pouliot-Laforte; L-N Veilleux; F Rauch; M Lemay
Journal:  J Musculoskelet Neuronal Interact       Date:  2015-06       Impact factor: 2.041

View more
  6 in total

Review 1.  Osteogenesis imperfecta: an update on clinical features and therapies.

Authors:  Ronit Marom; Brien M Rabenhorst; Roy Morello
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.664

2.  Alterations of a serum marker of collagen X in growing children with osteogenesis imperfecta.

Authors:  L E Nicol; R F Coghlan; D Cuthbertson; Sandesh C S Nagamani; B Lee; R C Olney; W Horton; E Orwoll
Journal:  Bone       Date:  2021-04-28       Impact factor: 4.626

3.  Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes.

Authors:  Rashmi Rao; David Cuthbertson; Sandesh C S Nagamani; Vernon Reid Sutton; Brendan H Lee; Jeffrey Krischer; Deborah Krakow
Journal:  Am J Obstet Gynecol MFM       Date:  2021-03-26

4.  Best practice guidelines in managing the craniofacial aspects of skeletal dysplasia.

Authors:  Ravi Savarirayan; David E Tunkel; Laura M Sterni; Michael B Bober; Tae-Joon Cho; Michael J Goldberg; Julie Hoover-Fong; Melita Irving; Shawn E Kamps; William G Mackenzie; Cathleen Raggio; Samantha A Spencer; Viviana Bompadre; Klane K White
Journal:  Orphanet J Rare Dis       Date:  2021-01-14       Impact factor: 4.123

5.  Positive airway pressure therapy for obstructive sleep apnea in patients with Osteogenesis imperfecta: a prospective pilot study.

Authors:  Heidi Arponen; Adel Bachour; Leif Bäck; Helena Valta; Antti Mäkitie; Outi Mäkitie; Janna Waltimo-Sirén
Journal:  BMC Musculoskelet Disord       Date:  2021-01-11       Impact factor: 2.362

6.  Treatments for hearing loss in osteogenesis imperfecta: a systematic review and meta-analysis on their efficacy.

Authors:  Maialen Ugarteburu; Luis Cardoso; Claus-Peter Richter; Alessandra Carriero
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.